Key Drivers
- Strong Net Cash
- Negative Cash Flow
- Thin Profitability
AIAI Summary
PHAR is now a Joenja commercialization execution bet: pediatric and Japanese expansion can offset RUCONEST's decline, but investors should wait for prescription/reimbursement traction and sustained positive operating cash flow before underwriting a premium valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Net Cash
- •Negative Cash Flow
- •Thin Profitability
PHAR offers strong liquidity and moderate leverage, but thin profitability, negative recent cash flow, and elevated valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Downtrend intact
- •Support retested
- •Rebound failed
PHAR remains in a last-month downtrend, with $10.55 support vulnerable unless price reclaims $11.27, while $11.20–$11.50 is the first resistance zone.
Rebound from $10.55 to $10.78 failed to hold
Sentiment & News
Key News Insights:
- •Pediatric expansion
- •First approved
- •October launch
Pharming's FDA approval to expand Joenja to eligible APDS children aged 4–11 broadens its addressable market and supports October commercialization.
The approval is a positive catalyst for Pharming, potentially increasing Joenja uptake and revenue
Similar Companies in Healthcare
Other companies in the same sector with AI ratings